<DOC>
	<DOCNO>NCT00086086</DOCNO>
	<brief_summary>The purpose study evaluate whether weight-based fixed start dos result comparable hemoglobin increase treatment effect patient heart failure anemia .</brief_summary>
	<brief_title>Subcutaneous ( SC ) Darbepoetin Alfa Subjects With Symptomatic Congestive Heart Failure ( CHF ) &amp; Anemia</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Symptomatic CHF least 3 month Reduced leave ventricular ejection fraction Stable heart failure medication Hemoglobin concentration 9.0 12.5 g/dL Hypertension Unstable angina pectoris recent myocardial infarction Likely receive cardiac transplant Major organ transplant ( e.g. , lung , liver , heart ) renal replacement therapy ( e.g. , dialysis ) Recent current treatment malignancy Systemic hematologic disease Anemia due acute chronic bleed Recent EpogenÂ® darbepoetin alfa therapy Recent blood transfusion</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Symptomatic Congestive Heart Failure</keyword>
	<keyword>CHF</keyword>
	<keyword>Anaemia</keyword>
	<keyword>Anemia</keyword>
</DOC>